Abbott Receives the US FDA Clearance of FreeStyle Libre 2 and FreeStyle Libre 3 Sensors for Diabetes
- The US FDA has granted clearance to FreeStyle Libre 2 & FreeStyle Libre 3 sensors for integration with an automated insulin delivery system which will be available in the US in 2023
- The sensors are also cleared for use by children as young as 2yrs. old, for use by women with diabetes who are pregnant & for wear time of up to 15 days. Abbott has ongoing collaborations with insulin pump manufacturers to integrate their systems with both sensors
- Companies partnering with Abbott incl. Insulet & Tandem to enable future integrations in multiple countries, incl. the US. Abbott received authorization to integrate FreeStyle Libre 3 with the mylife Loop from Ypsomed & CamDiab in Germany & plans launches in the UK, Switzerland & the Netherlands in H1’23
Ref: Abbott | Image: Abbott
Related Post:- Abbott Receives the US FDA and EU Approvals for Ablation Technologies to Treat Abnormal Heart Rhythms
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].